Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore

Published On 2025-07-05 06:27 GMT | Update On 2025-07-05 06:27 GMT

New Delhi: US-based Private investment firm Bain Capital has pared down its stake in Emcure Pharmaceuticals, offloading a 2.4 percent holding in the company for Rs 563 crore through an open market transaction.

Following the sale, Bain Capital’s shareholding in Emcure dropped from 8.68 percent to 6.31 percent, PTI reported.

According to bulk deal data from the National Stock Exchange (NSE), Bain Capital, acting through its BC Investments IV, sold 45 lakh shares of Emcure Pharmaceuticals at an average price of Rs 1,250.44 apiece. The total transaction value stood at Rs 562.7 crore.

Details of the buyers of Emcure Pharmaceuticals' shares could not be ascertained on the exchange.

In May, Emcure reported a 63 per cent rise in consolidated profit after tax (PAT) to Rs 197 crore during the March quarter.

It reported a PAT of Rs 121 crore on a consolidated basis a year ago.

During the January-March period, Emcure Pharmaceuticals' revenue from operations stood at Rs 2,116 crore, up 19.5 per cent year-on-year from Rs 1,771 crore.

Emcure's domestic business grew 24.8 per cent year-on-year, led by its women's health and cardio franchises. Meanwhile, the international business registered a growth of 15.6 per cent.

In July last year, Emcure's IPO received a stellar response from institutional buyers by garnering 67.87 times subscription.

Pune-based Emcure Pharmaceuticals is engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Medical Dialogues team earlier reported in June that Emcure Pharma had also received board approval to enter into agreement with minority shareholders of Zuventus Healthcare Ltd., one of its subsidiaries, to acquire their shareholding. Following the completion of this transaction, Zuventus will become a wholly owned subsidiary of Emcure.

Additionally, in April 2025, Tillomed Laboratories Limited, a subsidiary of Emcure Pharma and a European pharma company, entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore

Similar News

Govt Panel Makes This Approval Mandatory For New Drug Licenses

CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority

Lupin rolls out Nasal spray for rhinorrhea relief in US